QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium
Oncotelic Therapeutics (OTCQB: OTLC), a biopharmaceutical company developing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced…